Drug-eluting beads (DEBs) have been imposed as novel drug-delivering agents for TACE, which allows for higher concentrations of drugs within the target tumor and lower systemic …

From these results, DEB-TACE has demonstrated better—or at least similar—results in studies comparing DEB-TACE and cTACE. Furthermore, we may conclude that DEB-TACE could …

Drug-eluting bead transarterial chemoembolization (DEB-TACE) is a relative new endovascular treatment based on the use of microspheres to release chemotherapeutic agents within a …

This study aimed to compare the efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) vs conventional TACE (cTACE) in hepatocellular carcinoma …

Patients in DEB-TACE group presented with more favorable PFS (P = .028) and OS (P = .037) compared with cTACE group. Further analysis revealed that DEB-TACE (vs cTACE) was an …

Background and aim: Doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) is a novel locoregional treatment for unresectable hepatocellular carcinoma (HCC). However, to …

Jun 10, 2015 · To compare the overall survival of patients with hepatocellular carcinoma (HCC) who were treated with lipiodol-based conventional transarterial chemoembolization (cTACE) …

For the treatment of HCC, it is important to know the differences between DEB-TACE vs conventional TACE. Lipiodol-based conventional transarterial chemoembolization (cTACE) …

Patients in DEB-TACE group presented with more favorable PFS (P = .028) and OS (P = .037) compared with cTACE group. Further analysis revealed that DEB-TACE (vs cTACE) was an …

Transarterial chemoembolization (TACE) is the recommended treatment modality for patients with intermediate stage hepatocellular carcinoma (HCC), or stage B as defined by the Barcelona …